Biotech Values

[poorgradstudent]

RETA:

I think this type of situation is always a possibility.

The drug's impact on eGFR was not in doubt, and was published in the NEJM paper. The issue is how you finesse a drug that increases mortality in the long term versus this short term trial outcome.

This is a prime example of a "catalyst" field of view versus a long term fundamental view.